Galanin

What is Galanin?

Galanin is a 30-amino-acid neuropeptide widely distributed in the central nervous system, peripheral nervous system, and gastrointestinal tract. Originally isolated by Tatemoto and Mutt from porcine intestine in 1983 — the founders of the term "galanin" coined the name from its N-terminal glycine and C-terminal alanine (in non-human species). Human galanin lacks the C-terminal amidation found in many other species.

Galanin is research-only as a therapeutic. It is a significant target in psychiatric and metabolic drug discovery because of its modulation of monoaminergic systems implicated in depression, anxiety, and feeding.

Structure and Family

Galanin and its related peptide galanin-like peptide (GALP) form the galanin family. Galanin is highly conserved across species; the N-terminal 16 residues are identical across most mammals and contain the receptor-binding region.

Three galanin receptors (G-protein coupled):

• GalR1 — primarily Gi/o coupled, inhibitory; major locus coeruleus and raphe expression
• GalR2 — Gi/o, Gq, and G12/13 coupled; expressed widely; mood and feeding effects
• GalR3 — Gi/o coupled; CNS expression; mood and addiction effects

Mechanism and Functions

Mood and stress:

• Inhibition of noradrenergic LC neurons — galanin co-released with norepinephrine reduces LC firing and norepinephrine output
• Inhibition of serotonergic raphe neurons — modulates 5-HT release across forebrain
• Anxiolytic and antidepressant effects in some preclinical models (depending on receptor subtype and brain region)
• Linked to stress resilience and depressive phenotypes

Feeding and metabolism:

• Stimulates feeding behavior in central administration models
• Promotes intake of fat-rich foods
• Modulates insulin secretion and glucose homeostasis

Cognition and learning:

• Memory effects depend on brain region — hippocampal galanin can impair memory consolidation
• Modulates cholinergic basal forebrain neurons (with implications for Alzheimer's research)

Other functions:

• Pain modulation (spinal cord)
• Pituitary hormone secretion (GH, LH, prolactin)
• Gastrointestinal motility
• Reproduction

Research Investigation

The most active translational research areas for galanin:

Depression:

• GalR1 antagonists and GalR2/3 agonists are being studied
• Galmic, galnon, and other small-molecule galanin receptor ligands are in preclinical development
• Multiple academic groups studying the depression-galanin link

Obesity and metabolic disorders:

• Galanin's central role in feeding and fat preference
• GalR2 agonists studied for metabolic indications
• Spexin (a related peptide) is being investigated as a galanin receptor agonist with metabolic effects

Pain:

• Spinal galanin modulates nociceptive transmission
• GalR2 spinal agonists studied for chronic pain

Place in Drug Discovery

Galanin itself is unlikely to become an approved drug — the peptide does not cross the blood-brain barrier well, has broad receptor effects, and lacks subtype selectivity. The therapeutic interest is in subtype-selective small-molecule and peptide analogues that can be tuned to engage GalR1, GalR2, or GalR3 selectively.

Several research-stage galanin receptor ligands are in preclinical and early clinical development for mood, metabolic, and pain indications, but no galanin pathway drug has reached approval.

Distinction from NPY and Substance P

Galanin is one of several neuropeptides relevant to mood and stress:

These three neuropeptides represent overlapping but distinct nodes in the broader stress-response neuropeptide network.

Place in Research

Galanin is sold by research chemical suppliers and remains an active subject of investigation in academic neuroscience. Its therapeutic relevance is mediated through small-molecule and peptide receptor-subtype-selective ligands, rather than the native peptide itself.